JAMP CEFUROXIME 500 MG — DIN 02547201
CEFUROXIME (CEFUROXIME AXETIL) : 500 MG · JAMP PHARMA CORPORATION · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is JAMP CEFUROXIME?
JAMP CEFUROXIME 500 MG contains CEFUROXIME (CEFUROXIME AXETIL) : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02547201, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 27-Sep-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JAMP CEFUROXIME used for?
JAMP Cefuroxime (cefuroxime axetil tablets) is indicated for the treatment of patients with mild to moderately severe infections caused by susceptible strains of the designated organisms in upper respiratory tract infections (Pharyngitis, tonsillitis, otitis media, sinusitis), lower respiratory tract infections (Pneumonia or bronchitis), and skin structure infections. It should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Cefuroxime cost around the world?
Cefuroxime is listed on 5 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Morocco publishes a PPV (public price). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 42 | 47 | ZAR███.██ |
| Greece | producer price (ex-factory) | 24 | 24 | EUR███.██ |
| Morocco | PPV (public price) | 5 | 14 | MAD███.██ |
| Australia | ex-manufacturer | 3 | 8 | AUD███.██ |
| United Kingdom | hospital | 5 | 5 | GBP███.██ |
98 pack listings across 79 brand entries and 5 price bases, refreshed 08 Sep 2026. Ranges span every Cefuroxime pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Cefuroxime in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
15 holders have a Canadian DIN containing Cefuroxime, across 44 DINs, of which 9 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| FRESENIUS KABI CANADA LTD | 3 | 2 | CEFUROXIME FOR INJECTION, USP | Sourceable in Canada |
| APOTEX INC | 2 | 2 | APO-CEFUROXIME | Sourceable in Canada |
| AURO PHARMA INC | 2 | 2 | AURO-CEFUROXIME | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 2 | 2 | JAMP CEFUROXIME | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | CEFTIN | Sourceable in Canada |
| GLAXO CANADA INC | 7 | 0 | CEFTIN FOR ORAL SUSPENSION-PWS 250MG/PCK, CEFTIN PWS 125MG/5ML, CEFTIN TAB 250MG, CEFTIN TAB 500MG, ZINACEF INJ 1.5GM/VIAL, +2 more | No marketed DIN |
| GLAXOSMITHKLINE INC | 6 | 0 | CEFTIN - PWR 250MG/SACHET, CEFTIN - TAB 250MG, CEFTIN - TAB 500MG, ZINACEF INJECTION - PWS IM IV 750MG/VIAL, ZINACEF INJECTION - PWS IV 1.5GM/VIAL, +1 more | No marketed DIN |
| PHARMACEUTICAL PARTNERS OF CANADA INC | 6 | 0 | CEFUROXIME FOR INJECTION USP, KEFUROX | No marketed DIN |
| HIKMA CANADA LIMITED | 3 | 0 | CEFUROXIME FOR INJECTION, USP | No marketed DIN |
| NOVOPHARM LIMITED | 3 | 0 | NOVO-CEFUROXIME | No marketed DIN |
| ELI LILLY CANADA INC | 2 | 0 | KEFUROX INJ PWS 1.5GM/ADD-VANTAGE VIAL, KEFUROX INJ PWS 750MG/ADD-VANTAGE VIAL | No marketed DIN |
| TEVA CANADA LIMITED | 2 | 0 | RATIO-CEFUROXIME | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 500 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | 250 mg tablets: Available in HDPE bottles of 60 and 100 tablets. 500 mg tablets: Available in HDPE bottles of 60 and 100 tablets. |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Cefuroxime |
|---|---|
| ATC code | J01DC02 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02547201 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2547201 |
| Brand name | JAMP CEFUROXIME |
| Generic / active ingredient | CEFUROXIME (CEFUROXIME AXETIL) : 500 MG |
| Market authorization holder | JAMP PHARMA CORPORATION |
| Health Canada schedule | Prescription |
| ATC code | J01DC02 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01DC |
| Current status | MARKETED |
| Status date | 27-Sep-2024 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
9 of 44 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-CEFUROXIME | 500 MG | TABLET | APOTEX INC | MARKETED | 02244394 |
| APO-CEFUROXIME | 250 MG | TABLET | APOTEX INC | MARKETED | 02244393 |
| AURO-CEFUROXIME | 250 MG | TABLET | AURO PHARMA INC | MARKETED | 02344823 |
| AURO-CEFUROXIME | 500 MG | TABLET | AURO PHARMA INC | MARKETED | 02344831 |
| CEFTIN | 125 MG / 5 ML | GRANULES FOR SUSPENSION | SANDOZ CANADA INCORPORATED | MARKETED | 02212307 |
| CEFUROXIME FOR INJECTION, USP | 750 MG | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02241638 |
| CEFUROXIME FOR INJECTION, USP | 1.5 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02241639 |
| JAMP CEFUROXIME | 250 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02547198 |
| CEFTIN - PWR 250MG/SACHET | 250 MG | POWDER | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | 02212293 |
| CEFTIN - TAB 250MG | 250 MG | TABLET | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | 02212277 |
2 · Same class — other molecules in ATC J01DC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Cefuroxime | APO-CEFUROXIME · AURO-CEFUROXIME · CEFTIN · CEFTIN - PWR 250MG/SACHET · +23 more | 44 | 9 | Yes |
| Cefprozil | APO-CEFPROZIL · AURO-CEFPROZIL · AVA-CEFPROZIL · CEFPROZIL · +11 more | 34 | 7 | Yes |
| Cefoxitin | CEFOXITIN FOR INJECTION · CEFOXITIN FOR INJECTION USP · MEFOXIN INJ 1GM/VIAL ADD-VANTAG · MEFOXIN INJ 2GM/VIAL ADD-VANTAG · +3 more | 10 | 2 | Yes |
| Cefaclor | APO-CEFACLOR · CECLOR · CEFACLOR · CEFACLOR CAPSULES · +15 more | 41 | 0 | Not in Canada |
| Cefamandole | MANDOL ADD-VANTAGE INJ 1GM/VIAL · MANDOL INJ 1GM/AMP · MANDOL INJ 2GM/AMP | 3 | 0 | Not in Canada |
| Cefotetan | CEFOTAN INJ 2GM/VIAL · CEFOTAN INJECTION - 1G · CEFOTAN INJECTION - 2 G | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01DB | Cefadroxil · Cefalexin · Cefalotin · Cefazolin | 91 | 41 |
| J01DD | Cefixime · Cefotaxime · Cefpodoxime · Ceftazidime · Ceftizoxime · +1 more | 96 | 25 |
| J01DH | Doripenem · Ertapenem · Imipenem And Cilastatin · Meropenem · Meropenem And Vaborbactam | 51 | 24 |
| J01DE | Cefepime | 10 | 3 |
| J01DF | Aztreonam | 1 | 1 |
| J01DI | Ceftobiprole Medocaril · Ceftolozane And Beta-Lactamase Inhibitor | 2 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is JAMP CEFUROXIME called?
The same molecule, Cefuroxime, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Zinnat | Latin | Australia, Morocco |
| Pharmacor Cefuroxime | Latin | Australia |
| Betaroxime | Latin | South Africa |
| CEROXIM | Latin | Morocco |
| Ceroxim Forte Suspension | Latin | South Africa |
| Ceroxim Suspension | Latin | South Africa |
| Furocsem | Latin | South Africa |
| Zinnat (UK) | Latin | Australia |
| Sandoz Cefuroxime | Latin | South Africa |
| ZINACEF | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.